Key facts: SI-BONE Revenue Rises 14.5%; iFuse Wins FDA Clearance

What happened

SI-BONE reported third-quarter 2026 revenue of $55.7 million, up 14.5% from a year earlier. Its net loss narrowed to $3.6 million, and it reaffirmed 2026 revenue guidance of $231–$233 million. In September 2026 it won FDA 510(k) clearance, which means regulatory permission to sell, for the iFuse Granite Onyx device for failed spinal fusions.

Confirmed

Global impact / market context

Faster revenue growth alongside a smaller net loss suggests SI-BONE is moving toward profitability while still spending to grow. The new clearance gives it another product to sell into failed spinal fusion cases, a niche it sizes at $1.5 billion a year, which could support future revenue if surgeons adopt it.

Analyst inference

SI-BONE is a small medical device maker whose sales come from spinal fusion hardware, so its results track hospital procedure volumes and surgeon adoption. Investors weighing the stock balance 14.5% growth and narrowing losses against continued spending and the uncertain launch of iFuse Granite Onyx into a market the company estimates itself.

Analyst inference

What to watch

1. SI-BONE reaffirmed 2026 revenue guidance of $231–$233 million, so check whether quarterly sales stay on the path needed to land inside that range. Confirmed
2. Watch for updates on the iFuse Granite Onyx launch, including surgeon training and hospital ordering, since this device is meant to serve failed spinal fusions. Proposed
3. Track whether the narrowed net loss keeps shrinking as revenue grows, because continued spending on sales and product launches could slow the path to profit. Analyst inference

Evidence

• Original source link unavailable